The document titled "Use of Non-Sugar Sweeteners: WHO Guideline" provides recommendations from the World Health Organization on the use of non-sugar sweeteners (NSS) to reduce sugar intake, manage weight, and prevent diet-related noncommunicable diseases (NCDs). It discusses the potential effects of... NSS on body weight, blood sugar control, and long-term health risks such as type 2 diabetes and cardiovascular disease. The guideline highlights limited evidence on the benefits of NSS for weight control and raises concerns about possible health risks with long-term use, leading WHO to suggest limiting NSS consumption as a preventive health measure.
more
WHO has updated the mpox Case reporting form (CRF) and data collection tool, mainly by reducing the number of variables. A detailed list of changes is presented in the file. The content of the Case investigation form (CIF) has not been changed.
The prevalence of asthma and allergic rhinoconjunctivitis is high in western countries, and has been rising throughout the late 20th century. However, relatively little is known about the prevalence of allergic disorders in children in North Africa and the Middle East, and even less is known about t...he relative importance of socioeconomic factors in its aetiology in these countries, when compared to Europe, the USA and Australia.
more
On 13 August 2024, Africa Centres for Disease Control and Prevention (Africa CDC) declared the ongoing Mpox outbreak a Public Health Emergency of Continental Security (PHECS). This was followed the next day by the World Health Organization (WHO), which extended the alert internationally as a public ...health emergency of international concern (PHEIC). After these declarations, many countries have made efforts to mobilize resources to introduce or expand laboratory testing, surveillance, and response activities. In particular, as the number of suspected cases surges in the Democratic Republic of Congo (DRC), Burundi, and the Central African Republic, and an increasing number of new countries report cases, there is an urgent need to implement testing to strengthen the Mpox response. However, access to appropriate quality assured diagnostics is a challenge. There is limited information on important characteristics, such as available test kits’ performance and ability to detect relevant clades.
To address the challenge of mpox access in the continent, the Africa CDC Diagnostic Advisory Committee (DAC) met in Kigali from 19-23 August 2024 to review the available evidence on molecular tests for Mpox and to shortlist tests that may be useful for Mpox testing in countries. The shortlist aims to provide guidance to Africa CDC, countries and partners on appropriate high-quality molecular tests to procure and use for the mpox response.
more